Filing Details
- Accession Number:
- 0001127602-25-008317
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2025-03-05 16:37:22
- Reporting Period:
- 2025-02-24
- Filing Date:
- 2025-03-05
- Accepted Time:
- 2025-03-05 16:37:22
- Original Submission Date:
- 2025-02-25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1878313 | Maia Biotechnology Inc. | MAIA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1913253 | Ramiro Guerrero | 444 West Lake Street, Suite 1700 Chicago IL 60606 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-02-24 | 73,333 | $1.50 | 534,885 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrants | Acquisiton | 2025-02-24 | 73,333 | $1.87 | 73,333 | $1.87 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
73,333 | 2026-02-25 | 2031-02-25 | No | 4 | P | Direct |
Footnotes
- The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plna on February 24, 2025.
- This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 2 to "February 24, 2025".
- These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.